EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)ÄquivalenzstudieOpen Access

Adaptive Design for Phase II/III Platform Trial of Lassa Fever Therapeutics

Josephine Bourner, Michel Vaillant, Alex Paddy Abdel Salam, Marie Jaspard, Camille Fritzell, Shevin T Jacob, Tom E Fletcher, Michael Ramharter, Nnennaya Ajayi, Sylvanus Okogbenin, Cyril Erameh, Donald Grant und 7 weitere

Emerging Infectious Diseases · 2025-02 · 31 (2)

DOI: 10.3201/eid3102.240251 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Emerging Infectious Diseases, 2025-02. Verfasst von Josephine Bourner und 18 weiteren Autor:innen. Hauptthemen laut MEDLINE: Lassa Fever, Antiviral Agents, Ribavirin, Clinical Trials, Phase II as Topic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Wellcome Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The current recommendation for treating Lassa fever with ribavirin is supported only by weak evidence. Given the persistent effects in areas with endemic transmission and epidemic potential, there is an urgent need to reassess ribavirin and investigate other potential therapeutic candidates; however, a robust clinical trial method adapted to Lassa fever epidemiology has not yet been established. We propose an adaptive phase II/III multicenter randomized controlled platform trial that uses a superiority framework with an equal allocation ratio and accounts for challenges selecting the primary end point and estimating the target sample size by using an interim analysis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lassa FeverAntiviral AgentsRibavirinClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicHumansLassa virusRandomized Controlled Trials as TopicMulticenter Studies as TopicResearch Design

Stichwörter der Autor:innen

Lassa feverclinical trialsphase II/III multicenter randomized controlled platform trialviruses

Substanzen

Antiviral AgentsRibavirin

Förderung

  • Wellcome Trust

Zitieren

APA

Bourner, J., Vaillant, M., Abdel Salam, A. P., Jaspard, M., Fritzell, C., Jacob, S. T., Fletcher, T. E., Ramharter, M., Ajayi, N., Okogbenin, S., Erameh, C., Grant, D., Samuels, R., Ayodeji, O. O., Sprecher, A., Gonçalves, B. P., Edwards, T., Olliaro, P., & WALC Work Package 2 Working Group (2025). Adaptive Design for Phase II/III Platform Trial of Lassa Fever Therapeutics. Emerging Infectious Diseases, 31(2). https://doi.org/10.3201/eid3102.240251

Vancouver

Bourner J, Vaillant M, Abdel Salam AP, Jaspard M, Fritzell C, Jacob ST, et al. Adaptive Design for Phase II/III Platform Trial of Lassa Fever Therapeutics. Emerging Infectious Diseases. 2025;31(2). doi:10.3201/eid3102.240251

BibTeX
@article{Bourner2025,
  author = {Bourner, Josephine and Vaillant, Michel and Abdel Salam, Alex Paddy and Jaspard, Marie and Fritzell, Camille and Jacob, Shevin T and Fletcher, Tom E and Ramharter, Michael and Ajayi, Nnennaya and Okogbenin, Sylvanus and Erameh, Cyril and Grant, Donald and Samuels, Robert and Ayodeji, Oladele Oluwafemi and Sprecher, Armand and Gonçalves, Bronner P and Edwards, Tansy and Olliaro, Piero and WALC Work Package 2 Working Group, WALC Work Package 2 Working Group},
  title = {Adaptive Design for Phase II/III Platform Trial of Lassa Fever Therapeutics},
  journal = {Emerging Infectious Diseases},
  year = {2025},
  volume = {31},
  number = {2},
  doi = {10.3201/eid3102.240251}
}
Kostenlos starten →